ResearchPad - viewpoints https://www.researchpad.co Default RSS Feed en-us © 2020 Newgen KnowledgeWorks <![CDATA[The SARS-CoV-2 epidemic in Zimbabwe: Quo vadis?]]> https://www.researchpad.co/article/elastic_article_12503 The trajectory, and impact of the SARS-CoV-2 pandemic in sub-Saharan Africa is unclear, but it is seemingly varied between different countries, with most reporting low numbers. We use the situation in Zimbabwe to build an argument that the epidemic is likely to be attenuated in some countries with similar socio-economic and cultural structures. However, even an attenuated epidemic may overwhelm weak health systems, emphasising the importance of prevention. These prevention strategies should be tailored to the unique social and cultural networks of individual countries which may facilitate the spread of SARS-CoV 2. It is also equally important to maintain services for the major infectious diseases in the region such as tuberculosis and malaria. A breakdown of treatment and prevention services for these conditions may even overshadow the projected morbidity and mortality from COVID-19.

]]>
<![CDATA[COVID-19 Clinical Trial Oversight at a Major Academic Medical Center: Approach of the Michigan Medicine COVID-19 Clinical Trial Committees]]> https://www.researchpad.co/article/elastic_article_12501 Clinicians – eager to offer the best care in the absence of guiding data – have provided patients with COVID-19 diverse clinical interventions. This usage has led to perceptions of efficacy of some interventions that, while receiving media coverage, lack robust evidence. Moving forward, randomized controlled clinical trials (RCTs) are necessary to ensure that clinicians can treat patients effectively during this outbreak and the next. To do so, academic medical centers must address two key research issues: (1) how to effectively and efficiently determine which trials have the best chance of benefiting current and future patients, and (2) how to establish a transparent and ethical process for subject recruitment while maintaining research integrity and without overburdening patients or staff. We share here the current methods used by the University of Michigan to address these issues.

]]>
<![CDATA[SARS-CoV-2 pandemic : Time to revive the cyclophilin inhibitor alisporivir]]> https://www.researchpad.co/article/elastic_article_12500 December 2019 saw the emergence of a new epidemic of pneumonia of varying severity, called COVID-19, caused by a newly identified coronavirus, SARS-CoV-2. No therapeutic option is available to treat this infection that has already killed more than 235,000 people worldwide. This Viewpoint summarizes the strong scientific arguments supporting the use of alisporivir, a non-immunosuppressive analogue of cyclosporine A with potent cyclophilin inhibition properties that has reached Phase 3 clinical development, for the treatment of COVID-19. They include the strong cyclophilin dependency of the lifecycle of many coronaviruses, including SARS-CoV and MERS-CoV, and preclinical data showing strong antiviral and cytoprotective properties of alisporivir in various models of coronavirus infection, including SARS-CoV-2. Alisporivir should be tested without delay on both virological and clinical endpoints in patients with or at-risk of severe forms of SARS-CoV-2 infection.

]]>
<![CDATA[Social Media and the New World of Scientific Communication During the COVID-19 Pandemic]]> https://www.researchpad.co/article/elastic_article_12468 Twitter remains the double-edged sword of rapid scientific communication during the ongoing COVID-19 pandemic. Scientists will need to exercise great care in their communication using social media to share their research as this outbreak unfolds throughout 2020

]]>
<![CDATA[Hypertonic saline nasal irrigation and gargling should be considered as a treatment option for COVID-19]]> https://www.researchpad.co/article/elastic_article_11005 <![CDATA[Design for extreme scalability: A wordless, globally scalable COVID-19 prevention animation for rapid public health communication]]> https://www.researchpad.co/article/elastic_article_7562 <![CDATA[The time is now: expedited HIV differentiated service delivery during the COVID‐19 pandemic]]> https://www.researchpad.co/article/N678aa220-4d89-40b1-8240-59587ec08e31 <![CDATA[Lessons learned from HIV can inform our approach to COVID‐19 stigma]]> https://www.researchpad.co/article/Nc7b9f12a-d826-4ed5-b5fc-3d1db769549e <![CDATA[COVID-19, superinfections and antimicrobial development: What can we expect?]]> https://www.researchpad.co/article/N766bc72d-bafa-4af6-9c11-0c31a1f5123e Coronavirus disease 2019 (COVID-19) arose at a time of great concern about antimicrobial resistance (AMR). No studies have specifically assessed COVID-19-associated superinfections or AMR. Based on limited data from case series, it is reasonable to anticipate that an appreciable minority of patients with severe COVID-19 will develop superinfections, most commonly pneumonia due to nosocomial bacteria and Aspergillus. Microbiology and AMR patterns are likely to reflect institutional ecology. Broad-spectrum antimicrobial use is likely to be widespread among hospitalized patients, both as directed and empiric therapy. Stewardship will have a crucial role in limiting unnecessary antimicrobial use and AMR. Congressional COVID-19 relief bills are considering antimicrobial reimbursement reforms and antimicrobial subscription models, but it is unclear if these will be included in final legislation. Prospective studies on COVID-19 superinfections are needed, data from which can inform rational antimicrobial treatment and stewardship strategies, and models for market reform and sustainable drug development.

]]>
<![CDATA[Psychiatry's Future: Biology, Psychology, Legislation, and “The Fierce Urgency of Now”]]> https://www.researchpad.co/article/N3114ea5c-474e-4560-8b7e-daf2706f9b58 ]]> <![CDATA[Application of Big Data and Artificial Intelligence technologies to dementia prevention research: an opportunity for low-and-middle-income countries]]> https://www.researchpad.co/article/N1fabc317-e634-434b-906c-912f5cbdba42 ]]> <![CDATA[A cascade of causes that led to the COVID-19 tragedy in Italy and in other European Union countries]]> https://www.researchpad.co/article/Nde7da0ad-8f8f-453d-8f7d-8fd99514adf3 ]]> <![CDATA[Academic careers in global pulmonary and critical care medicine]]> https://www.researchpad.co/article/Nd9257480-6073-4692-9479-91c6145af245 ]]> <![CDATA[World Health Organization simulations: an increasingly popular learning tool for the development of future global health practitioners]]> https://www.researchpad.co/article/Nb0d0b701-fb71-42bc-9f51-79f2849958ea ]]> <![CDATA[Bugs as Drugs, potential self-regenerated innovative cancer therapeutics approach for global health]]> https://www.researchpad.co/article/Naee5e0a5-3963-4a6d-be46-9cfce2045dd2 ]]> <![CDATA[“What’s in a name?”: Exploring inconsistent and contradictory definitions and clinical guidelines for hypertensive disorders of pregnancy from published literature from Nigeria and Bangladesh]]> https://www.researchpad.co/article/Ncf83487e-5eaf-414b-a92c-11d66555945d ]]> <![CDATA[Addressing smokeless tobacco use and building research capacity in South Asia (ASTRA)]]> https://www.researchpad.co/article/N8ff6262c-0e16-4c92-a83e-2ac40d1b5ef5 ]]> <![CDATA[Universal health coverage in the framework of the 2030 global agenda for sustainable development: agreements and challenges]]> https://www.researchpad.co/article/Nae469c75-2c23-4c35-966f-993d3f937767 ]]> <![CDATA[National user fee abolition and health insurance scheme in Burkina Faso: How can they be integrated on the road to universal health coverage without increasing health inequities?]]> https://www.researchpad.co/article/N1c4ce8c5-5214-4430-a5ac-cc997ec85ca0 ]]> <![CDATA[]]> https://www.researchpad.co/article/Ncfc29c47-f9bf-4abe-8dad-9d98b75c3951 ]]>